Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

Trial Profile

Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 03 Jun 2015 Status changed from recruiting to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 10 Apr 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
    • 22 Oct 2013 Planned initiation date changed from 1 Aug 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top